Nothing Special   »   [go: up one dir, main page]

AU2002345658A1 - Methods for targeted expression of therapeutic nucleic acid - Google Patents

Methods for targeted expression of therapeutic nucleic acid

Info

Publication number
AU2002345658A1
AU2002345658A1 AU2002345658A AU2002345658A AU2002345658A1 AU 2002345658 A1 AU2002345658 A1 AU 2002345658A1 AU 2002345658 A AU2002345658 A AU 2002345658A AU 2002345658 A AU2002345658 A AU 2002345658A AU 2002345658 A1 AU2002345658 A1 AU 2002345658A1
Authority
AU
Australia
Prior art keywords
methods
nucleic acid
therapeutic nucleic
targeted expression
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002345658A
Inventor
Richard R. Drake
Saurabh K. Gupta
Robyn Mcmasters
Kelly E. Mercer
Mary Pat Moyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
INCELL Corp LLC
University of Arkansas at Little Rock
Original Assignee
Eastern Virginia Medical School
INCELL Corp LLC
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School, INCELL Corp LLC, University of Arkansas at Fayetteville, University of Arkansas at Little Rock filed Critical Eastern Virginia Medical School
Publication of AU2002345658A1 publication Critical patent/AU2002345658A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002345658A 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid Abandoned AU2002345658A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29783101P 2001-06-13 2001-06-13
US60/297,831 2001-06-13
US36113702P 2002-03-01 2002-03-01
US60/361,137 2002-03-01
PCT/US2002/018650 WO2002101076A2 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Publications (1)

Publication Number Publication Date
AU2002345658A1 true AU2002345658A1 (en) 2002-12-23

Family

ID=26970335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002345658A Abandoned AU2002345658A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Country Status (5)

Country Link
EP (1) EP1461427A4 (en)
JP (1) JP2005504520A (en)
AU (1) AU2002345658A1 (en)
CA (1) CA2460095A1 (en)
WO (1) WO2002101076A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5976986B2 (en) * 2005-10-01 2016-08-24 チャールズ スタウト， Regulatable fusion promoter
KR20200074283A (en) * 2013-03-24 2020-06-24 오이신 바이오테크놀로지스 Systems and methods for the targeted production of a therapeutic protein within a target cell
AU2017272104A1 (en) * 2016-05-25 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Activity-dependent expression constructs and methods of using the same
JP2020503390A (en) 2017-01-09 2020-01-30 オイシン バイオテクノロジーズ， インコーポレイテッド Fusogenic lipid nanoparticles, and methods for making and using the same, for target cell-specific production of therapeutic proteins and for treating diseases, conditions, or disorders associated with target cells
CA3097411A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the target cell-specific production of a therapeutic protein
CN110964747A (en) * 2019-11-26 2020-04-07 深圳市人民医院 Suicide gene adenovirus with high-efficiency specific expression in glioma cell and construction method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4
CN1418224A (en) * 2000-03-02 2003-05-14 Ml实验室公开有限公司 TCF responsive element

Also Published As

Publication number Publication date
WO2002101076A3 (en) 2004-07-22
CA2460095A1 (en) 2003-12-19
JP2005504520A (en) 2005-02-17
WO2002101076A2 (en) 2002-12-19
EP1461427A2 (en) 2004-09-29
EP1461427A4 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
AU2002367466A1 (en) Amplification of nucleic acid fragments using nicking agents
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002348163A1 (en) Therapeutic methods for nucleic acid delivery vehicles
AU2003286535A1 (en) Methods of manipulating nucleic acids
AU2003291354A1 (en) Methods and compostions for therapeutic use of rna interference
AU2002257936A1 (en) Methods of well treatment
AU2002318386A1 (en) Methods for characterization of nucleic acid molecules
AU2003280603A1 (en) Method of amplifying nucleic acid
AU2002314997A1 (en) Methods for low background cloning of dna using long oligonucleotides
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003260945A1 (en) Methods of use for thermostable rna ligases
GB0123401D0 (en) Methods of inducing gene expression
AU2003205817A1 (en) Methods of nucleic acid amplification
AU2002345658A1 (en) Methods for targeted expression of therapeutic nucleic acid
AU2002229986A1 (en) Method of treating neurological diseases
AU2003256280A1 (en) Methods of delivering gene therapy agents
AU2003230004A1 (en) Methods of therapy for inducing tolerance
AU2003252983A1 (en) Amplification of nucleic acids
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
AU2002242075A1 (en) Methods for homology-driven reassembly of nucleic acid sequences
AU2002219992A1 (en) Targeted regulation of gene expression
AUPR731901A0 (en) Method of treatment
AU2003245575A1 (en) Oligonucleotide directed misfolding of rna
AU2002322013A1 (en) Therapeutic dna vaccination
AU2003293581A1 (en) Method of identifying therapeutic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase